10X Genomics

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

10X Genomics reports solid earnings, eyes growth through innovation

10X Genomics delivered solid earnings in Q4 2022, with revenue growth and strong product innovation driving market presence and customer engagement.
Despite challenges like operational constraints and margin expectations, the company focuses on financial sustainability and market adaptability for future growth.
Opportunities lie in new sample types exploration, product success with Xenium and Visium HD, and customer response to Chromium Flex, indicating potential for revenue growth and market expansion.
Balanced guidance discussions and a focus on key products position 10X Genomics for strategic growth in 2023, with a global market outlook and emphasis on innovation and customer satisfaction.

10x Genomics reports robust Q1 revenue growth, eyes operational efficiency

10x Genomics delivered strong revenue growth in Q1 2023, driven by spatial portfolio and Chromium consumables, with raised revenue guidance for the year.
The company faces challenges in China and margin pressures but sees opportunities in product enhancements, market expansion, and revenue diversification.
Overall, 10x Genomics is strategically positioned for growth, with a focus on operational efficiency, customer adoption, and revenue optimization.

10X Genomics reports robust Q2 growth amidst China challenges

10X Genomics saw strong revenue growth in Q2 2023, driven by single cell and spatial portfolios.
While facing challenges in China, opportunities lie in expanding applications and clinical adoption.
Operational improvements and product advancements position the company for future growth.
Focus on margin improvement and revenue diversification key for sustained success.

10x Genomics reports robust Q3 revenue growth and strategic realignment

10x Genomics showcased strong revenue growth driven by Xenium's success, with plans to enhance product offerings and rebalance resources for future growth.
Despite challenges in gross margin and flat Chromium revenue, the company remains optimistic about its outlook and growth potential in spatial placements.
Opportunities lie in leveraging Xenium's capabilities, driving consumable revenue through discounts, and focusing on the Chromium franchise for sustained growth.

10x Genomics reports strong Q4 earnings, eyes growth opportunities

10x Genomics anticipates revenue of $670-690 million for 2024.
Guidance philosophy balances upsides and downsides for growth.
Strategic focus on product portfolio and long-term gross margin profile.
Emphasis on investments for future growth and maintaining innovation.

10x Genomics reports Q1 revenue growth, tackles pricing challenges

10x Genomics saw strong revenue growth in spatial but faced challenges with new Chromium technology orders.
The company aims to drive adoption by reducing prices and expanding the total market for single-cell technology.
Customers are showing interest in multiple platforms, setting up genomics infrastructure with various use cases.
Despite obstacles, 10x Genomics remains optimistic about the potential of its technology platforms and market growth.

10X Genomics reports Q3 revenue decline, focuses on growth strategies

10X Genomics faced revenue decline in Q3 due to sales restructuring and cautious customer spending, with full-year revenue expected to decline by 3%. Despite challenges, the company is focused on driving growth through new product launches, evolving commercial structure, and expanding access to single cell analysis. Confidence in the company's path forward remains strong, with expectations for sequential improvements and a focus on long-term opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Delivers major improvements for discoveries in immunology, oncology, autoimmunity, and infectious diseases Delivers major improvements for discoveries in immunology, oncology, autoimmunity, and infectious diseases

10x Genomics Launches Next Generation Immune Profiling Product to Combat COVID-19

GSK, Johns Hopkins Medical Institutions, Mass General Cancer Center join global network to accelerate discoveries in COVID-19, oncology, immuno-oncology and neurology GSK, Johns Hopkins Medical Institutions, Mass General Cancer Center join global network to accelerate discoveries in COVID-19, oncology, immuno-oncology and neurology

10x Genomics Selects First 45 Members for Visium Clinical Translational Research Network

10x Genomics (TXG) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

10x Genomics (TXG) Looks Good: Stock Adds 6.2% in Session

New solution accelerates research validation in cancer, immunology and drug discovery New solution accelerates research validation in cancer, immunology and drug discovery

Focusing on the Genes that Matter Most: 10x Genomics Launches Targeted Gene Expression Solution

1Life Healthcare

Pioneering Effort for Safe Workplace Reentry Pioneering Effort for Safe Workplace Reentry

10x Genomics Becomes First One Medical Customer to Deploy Cohort-Based COVID-19 Employee Testing

10x Genomics  Becomes First One Medical Customer to Deploy Cohort-Based COVID-19 Employee Testing 

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q1 2020 Results - Earnings Call Transcript

Provides Preliminary Revenue Range for the First Quarter 2020

10x Genomics Provides COVID-19 Business Impact Update and Response

Former Genomic Health CEO brings decades of healthcare experience to Board Former Genomic Health CEO brings decades of healthcare experience to Board

10x Genomics Appoints Kim Popovits to Board of Directors

Ships Chromium Connect; Unveils Dozen New Applications to Advance Genomics Ships Chromium Connect; Unveils Dozen New Applications to Advance Genomics

10x Genomics Debuts Range of  New Products at AGBT

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q4 2019 Results - Earnings Call Transcript

ABIOMED

Becton, Dickinson and Co.

Cardinal Health

Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.

Medical Products Stock Feb 6 Earnings Roster: BDX, CAH & More

The company scored an important win in a patent dispute.

Here's Why 10x Genomics Rose 17.5% in December

10x Genomics (NASDAQ: TXG), a biotechnology company that designs and manufactures gene sequencing technology, was listed following its IPO in September. While the stock saw some volatility post its debut, it currently trades at about $65, a ~65% increase from its IPO price of $39 per share.

Why 10X Genomics Has Rallied Post Its IPO

First Product Developed from Spatial Transcriptomics Acquisition First Product Developed from Spatial Transcriptomics Acquisition 

10x Genomics Begins Shipments of Visium Spatial Gene Expression Solution

10x Genomics Inc. (TXG) CEO Serge Saxonov on Q3 2019 Results - Earnings Call Transcript

10X Genomics: Little Droplets Of Information

10X Genomics is growing revenue at a healthy clip, but a series of patent-infringement suits are hanging over the lab-hardware business.

Is This $5 Billion Biotech IPO a Buy?

PLEASANTON, Calif., Sept.  16, 2019  (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the closing of its initial public offering of 11,500,000 shares of its Class A common stock, which includes the exercise in full of the underwriters’ option to purchase 1,500,000 additional shares of its Class A common stock, at a public offering price of $39.00 per share. Including the option exercise, the aggregate gross proceeds from the offering were $448.5 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares were offered by 10x Genomics. The shares began trading on The Nasdaq Global Select Market on September 12, 2019, under the ticker symbol “TXG.”

10x Genomics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

10X Genomics Inc. (NASDAQ: TXG) shares entered the market with a bang on Thursday.

10X Genomics Enters the Market With a Bang

10x Genomics (NASDAQ: TXG) made its public debut Thursday morning, opening at $54 after being priced at $39 per share.

News for 10X Genomics Stock (TXG)